Last updated: September 9, 2026
Vaborbactam is an approved beta-lactamase inhibitor marketed only in combination with meropenem as Vabomere. The product is positioned against serious infections caused by carbapenem-resistant Enterobacterales, particularly KPC-producing Klebsiella pneumoniae and related organisms. Its commercial opportunity is concentrated in hospital and infectious-disease settings rather than broad outpatient use.
The near-term outlook is stable but limited by narrow use, antimicrobial stewardship, competing beta-lactamase inhibitor combinations, and eventual generic exposure. Vabomere has a stronger clinical position against KPC-producing organisms than against metallo-beta-lactamases or many OXA-type carbapenemases. Its commercial value depends on resistance surveillance, hospital formulary access, and the ability to preserve meropenem-vaborbactam activity through targeted use.
What is vaborbactam and how does Vabomere work?
Vaborbactam is a cyclic boronic acid beta-lactamase inhibitor. It is co-formulated with meropenem, a carbapenem antibiotic, in Vabomere for intravenous administration.
Vaborbactam inhibits several serine beta-lactamases, most importantly KPC enzymes. KPC enzymes are a major mechanism of carbapenem resistance in Enterobacterales. Vaborbactam does not reliably inhibit metallo-beta-lactamases such as NDM, VIM, and IMP. Its activity against OXA-48-like enzymes is also limited compared with its activity against KPC.
The combination is therefore a targeted treatment for infections in which laboratory testing identifies a susceptible pathogen. It is not a universal therapy for all carbapenem-resistant Gram-negative infections.
What organisms and resistance mechanisms does Vabomere target?
The principal target is carbapenem-resistant Enterobacterales driven by KPC production. Relevant pathogens include:
- Klebsiella pneumoniae
- Escherichia coli
- Enterobacter cloacae complex
- Other Enterobacterales with susceptible KPC-mediated resistance
Vabomere is less suitable for:
- NDM, VIM, and IMP metallo-beta-lactamase producers
- Many OXA-48-like carbapenemase producers
- Pathogens with non-beta-lactamase resistance mechanisms that preserve meropenem resistance
- Acinetobacter baumannii, unless supported by specific susceptibility and clinical judgment
IDSA treatment guidance has identified meropenem-vaborbactam as a preferred option for many KPC-producing Enterobacterales infections, particularly when susceptibility is confirmed (Infectious Diseases Society of America, 2024).
What is the FDA regulatory status of vaborbactam?
The FDA approved Vabomere on August 29, 2017, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated susceptible organisms (FDA, 2017).
The approval followed a priority-review process. Vabomere also received Qualified Infectious Disease Product designation under the Generating Antibiotic Incentives Now provisions. That designation provided an additional five years of regulatory exclusivity beyond the applicable base period, subject to statutory conditions.
Key FDA milestones
| Milestone |
Date |
Significance |
| FDA approval of Vabomere |
August 29, 2017 |
Initial approval for adult complicated urinary tract infections |
| Core clinical evidence |
2010s |
TANGO I and TANGO II studies supported efficacy and activity against resistant Gram-negative pathogens |
| QIDP designation |
Before approval |
Added statutory exclusivity and priority-review benefits |
| Current clinical role |
Ongoing |
Targeted hospital therapy for serious infections caused by susceptible resistant Enterobacterales |
The initial FDA indication was narrower than the broader clinical use discussed in infectious-disease guidelines. Hospital use in bloodstream, intra-abdominal, and other serious infections may rely on susceptibility results, institutional protocols, and accepted clinical practice rather than an indication that covers every infection site.
What clinical development supports meropenem-vaborbactam?
The principal development program included TANGO I and TANGO II.
TANGO I evaluated meropenem-vaborbactam in complicated urinary tract infections. The combination demonstrated noninferiority to piperacillin-tazobactam in the relevant treatment population and supported the FDA approval (Kaye et al., 2018).
TANGO II evaluated adults with infections caused by carbapenem-resistant Enterobacterales. The study compared meropenem-vaborbactam with best available therapy. Although the trial was stopped early because of favorable outcomes in the investigational arm, the study was relatively small. Its results supported the product’s role in KPC-focused treatment but did not establish broad superiority across every carbapenem-resistant pathogen or infection type (Wunderink et al., 2018).
What are the main clinical development constraints?
The development profile has four commercial implications:
- Vaborbactam has its clearest value when the resistance mechanism is KPC.
- Rapid diagnostics and susceptibility testing are important because empirical use across all carbapenem-resistant infections is inefficient.
- Stewardship limits routine use in infections treatable with narrower or lower-cost agents.
- Resistance can emerge through changes in porin expression, beta-lactamase evolution, or combined mechanisms affecting meropenem exposure.
The clinical development opportunity is therefore more likely to involve label optimization, pediatric evidence, real-world outcomes, and diagnostic-guided use than a major expansion into a broad anti-infective platform.
What patents protect Vabomere and vaborbactam?
Vabomere’s protection is based on a combination of compound, formulation, treatment-method, and product patents. The relevant estate is more valuable as a combination-product portfolio than as protection for a standalone vaborbactam product, because vaborbactam is commercialized with meropenem.
Publicly reported U.S. Orange Book records have associated Vabomere with multiple patents, including the following commonly cited patent numbers:
| U.S. patent |
General subject matter |
Reported nominal expiration period* |
| 8,969,616 |
Vaborbactam-related compound and pharmaceutical technology |
2028 |
| 9,266,951 |
Boronic acid beta-lactamase inhibitor technology |
2031 |
| 9,556,153 |
Vaborbactam or beta-lactamase inhibitor combinations |
2030 |
| 10,183,020 |
Combination or use-related protection |
2030 |
*Expiration timing can differ by patent-term adjustment, patent-term extension, terminal disclaimer, pediatric extension, and the specific listed claim. The legally operative date is the term shown in the current FDA Orange Book and the underlying patent records.
What formulations are protected by vaborbactam patents?
The patent estate can cover:
- Vaborbactam compositions
- Meropenem-vaborbactam combinations
- Intravenous pharmaceutical formulations
- Dosing regimens
- Treatment of infections caused by beta-lactamase-producing organisms
- Manufacturing and purification processes for the active ingredient
Formulation protection matters because a generic applicant may avoid a compound claim yet face claims directed to the fixed combination, dosage form, preparation method, or treatment method. The practical strength of those claims depends on claim construction and whether an ANDA product would infringe them.
How strong is the vaborbactam patent estate?
The estate is moderately strong through the late 2020s and potentially relevant into the early 2030s, but its strength is not uniform.
Compound and composition claims typically provide the strongest barrier. Method-of-use claims are narrower and may be harder to enforce against an ANDA applicant, particularly where the generic label uses prescribing language designed to avoid the patented indication. Formulation and manufacturing claims can add settlement leverage but may not prevent all generic entry if alternative processes are available.
The most important commercial patent risk is a generic meropenem-vaborbactam product that reaches the market after a negotiated settlement or after invalidating a key composition patent. The existence of multiple patents does not guarantee a corresponding number of independent market barriers.
When does vaborbactam lose exclusivity?
Regulatory exclusivity from the 2017 approval was substantially less important than patent protection. The QIDP framework provided five additional years of exclusivity, placing the principal statutory period in the early 2020s. Patent protection, rather than FDA exclusivity, is the principal barrier for later generic entry.
The likely market-access sequence is:
| Period |
Commercial event |
| 2017-2022 |
FDA regulatory exclusivity and early patent-protected launch period |
| 2023-2028 |
Increasing Paragraph IV and patent-validity risk as early patents approach expiration |
| 2029-2031 |
Exposure to later composition, formulation, and combination patents |
| After final enforceable patent expiry |
Potential broad generic competition, subject to litigation and settlement outcomes |
A pediatric exclusivity extension could add six months if statutory requirements were satisfied and the FDA granted the extension for eligible patents. The extension would apply to qualifying patent and exclusivity periods, not create an unlimited new patent term.
What is the Orange Book status of Vabomere?
Vabomere is an FDA-approved drug listed in the Orange Book as a prescription fixed-dose combination containing meropenem and vaborbactam. The relevant Orange Book entries identify patents that a generic applicant must address in an abbreviated new drug application.
An ANDA applicant generally must submit one of four patent certifications:
- Paragraph I, if no patent information is listed
- Paragraph II, if the patent has expired
- Paragraph III, if the applicant will wait until patent expiration
- Paragraph IV, if the applicant argues that the patent is invalid, unenforceable, or not infringed
A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman Act. The litigation can produce a 30-month stay of FDA approval, subject to statutory exceptions and court action.
Which companies are challenging vaborbactam patents?
Publicly visible generic competition is expected to come from large injectable-antibiotic manufacturers and specialty generic companies with sterile manufacturing capacity. The commercial candidates include companies with experience in:
- Carbapenem products
- Hospital anti-infectives
- Sterile powder-for-injection manufacturing
- Complex combination ANDAs
- Paragraph IV litigation
No generic company has the same commercial incentive to pursue vaborbactam as a mass-market antibiotic because the product has a narrow hospital market and requires specialized sterile manufacturing. A first-to-file Paragraph IV applicant could still have significant leverage if it obtains 180-day generic exclusivity or reaches a launch settlement.
A definitive list of current Paragraph IV filers and litigation parties must be taken from active FDA, PACER, and district-court records. Patent disputes involving Vabomere should not be inferred solely from Orange Book listings.
What patent litigation and settlement risks affect Vabomere?
The primary litigation risks are:
- Invalidity challenges to compound claims
- Non-infringement arguments against combination claims
- Attacks on written description or enablement
- Challenges to obviousness based on known beta-lactamase inhibitor chemistry
- Disputes over whether an ANDA label induces infringement of method-of-use claims
- Claims that listed patents do not properly cover the approved product
A settlement could permit an authorized or licensed generic launch before the last nominal patent expiration. The settlement could include a launch date, royalty, supply arrangement, or license to specified patents. In a small hospital market, the patent holder may prefer controlled generic entry to prolonged litigation that produces limited incremental revenue.
How does vaborbactam compare with competing beta-lactamase inhibitors?
| Product |
Inhibitor |
Main resistance positioning |
Key commercial distinction |
| Vabomere |
Vaborbactam plus meropenem |
Strong KPC focus |
Carbapenem backbone and KPC activity |
| Avycaz |
Avibactam plus ceftazidime |
KPC, OXA-48-like, selected class A/C enzymes |
Broader inhibitor profile in some settings |
| Recarbrio |
Relebactam plus imipenem/cilastatin |
KPC and class C activity |
Alternative carbapenem combination |
| Fetroja |
Cefiderocol |
Broad activity against many resistant Gram-negative organisms |
Siderophore cephalosporin; different resistance profile |
| Zerbaxa |
Ceftolozane/tazobactam |
Difficult Pseudomonas and selected Gram-negative infections |
Greater relevance in Pseudomonas than KPC |
| Azactam plus Avycaz |
Aztreonam plus avibactam |
Metallo-beta-lactamase-producing organisms |
Combination strategy for MBL infections |
Vabomere is strongest when KPC is confirmed and meropenem remains an effective backbone. Avycaz has an important role against OXA-48-like enzymes and selected pathogens not covered well by vaborbactam. Cefiderocol and aztreonam-avibactam strategies address resistance mechanisms outside vaborbactam’s main range.
What is the vaborbactam market projection?
Vaborbactam is unlikely to become a high-volume antibiotic. Its market is constrained by targeted prescribing, inpatient administration, diagnostic requirements, and competition from other reserve agents.
A practical U.S. revenue framework is:
| Scenario |
Commercial assumptions |
Estimated annual U.S. Vabomere revenue |
| Low case |
Limited KPC prevalence, strong stewardship, price pressure |
$50 million-$100 million |
| Base case |
Stable hospital adoption and sustained KPC burden |
$100 million-$200 million |
| High case |
Rising CRE incidence, favorable guidelines, limited generic competition |
$200 million-$350 million |
These ranges are market-model estimates, not reported product sales. They assume continued use as a premium hospital antibiotic and exclude international revenue, licensing income, and any future pediatric or combination-product expansion.
The largest variables are:
- KPC prevalence in U.S. hospitals
- Hospital formulary adoption
- Use in bloodstream and severe infections
- Resistance to alternative agents
- Duration of patent-protected pricing
- Timing of generic entry
- Net price after hospital contracting
- Diagnostic testing rates
A generic launch could reduce branded net sales rapidly because hospital buyers are price-sensitive and reserve-antibiotic demand is concentrated among institutional purchasers. If entry occurs before 2030 through a settlement, the erosion curve could be materially steeper than a post-2031 launch.
What manufacturing and geographic barriers affect vaborbactam?
Vabomere requires sterile injectable manufacturing and reliable supply of both meropenem and vaborbactam. Manufacturing complexity includes:
- Control of sterile powder production
- Compatibility and stability of the fixed combination
- Analytical differentiation of vaborbactam and degradation products
- Validation of reconstitution and infusion instructions
- Supply-chain qualification for hospital use
The principal geographic market is the United States, where carbapenem-resistant Enterobacterales and hospital reimbursement support premium anti-infective use. Europe and Japan provide additional opportunity but have different antimicrobial stewardship rules, procurement systems, and market-access requirements.
The product’s international value is likely to be highest in tertiary-care hospitals and countries with documented KPC prevalence. Markets dominated by NDM or OXA-48-like resistance provide a weaker fit.
What is the investment outlook for vaborbactam?
Vaborbactam has a defensible niche rather than a broad expansion profile. Its value is supported by:
- Clinical preference for KPC-producing CRE infections
- Limited therapeutic alternatives in severe hospital infections
- Product differentiation from standard carbapenems
- A patent estate extending beyond the original FDA exclusivity period
- Specialized sterile manufacturing requirements
The main risks are:
- Narrow eligible-patient population
- Resistance outside vaborbactam’s spectrum
- Competing products with broader carbapenemase coverage
- Stewardship-driven restrictions
- Generic entry in the late 2020s or early 2030s
- Limited transparency around product-level revenue
- Potential changes in treatment guidelines as new agents enter the market
For licensing or acquisition analysis, the most valuable assets are later-expiring composition and combination patents, real-world evidence in KPC bloodstream infections, hospital contracts, and manufacturing capacity. A standalone vaborbactam strategy has less value than a broader CRE anti-infective platform that includes diagnostics, combination therapies, or complementary activity against MBL-producing organisms.
Key Takeaways
- Vaborbactam is commercially established only as meropenem-vaborbactam, marketed as Vabomere.
- Its strongest clinical and commercial position is against KPC-producing Enterobacterales.
- It does not provide broad coverage against NDM, VIM, IMP, or many OXA-48-like carbapenemases.
- FDA regulatory exclusivity from the 2017 approval has expired; patent protection remains the primary market barrier.
- Reported U.S. patent protection extends from the late 2020s into the early 2030s, depending on the patent and applicable adjustments.
- The base-case U.S. annual revenue opportunity is approximately $100 million to $200 million.
- Generic entry is the principal long-term commercial risk.
- The product has a durable hospital niche but limited potential to become a broad-volume antibiotic.
FAQs
Is vaborbactam approved as a standalone drug?
No. FDA approval is for the fixed combination meropenem-vaborbactam, marketed as Vabomere.
Does vaborbactam treat NDM-producing bacteria?
No. Vaborbactam does not inhibit metallo-beta-lactamases such as NDM, VIM, and IMP. Treatment of these organisms requires a different active strategy, often guided by susceptibility testing.
Is Vabomere a biologic or biosimilar product?
No. Vabomere is a small-molecule injectable antibacterial. Biosimilar pathways do not apply. Generic competition would proceed through the ANDA and Hatch-Waxman framework.
What is the main commercial advantage of Vabomere over meropenem alone?
Vaborbactam restores or improves meropenem activity against selected KPC-producing Enterobacterales by inhibiting the beta-lactamase that would otherwise hydrolyze meropenem.
Could a generic Vabomere launch before the last listed patent expires?
Yes. A generic could launch after a successful Paragraph IV challenge, under a settlement license, or through an authorized-generic arrangement. The last nominal patent expiration does not by itself determine the earliest commercial launch date.
References
-
Food and Drug Administration. (2017). FDA approves new antibacterial drug. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Vabomere: Prescribing information. U.S. Department of Health and Human Services.
-
Infectious Diseases Society of America. (2024). IDSA 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clinical Infectious Diseases.
-
Kaye, K. S., et al. (2018). Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection. JAMA, 319(8), 788-799.
-
U.S. Patent No. 8,969,616. United States Patent and Trademark Office.
-
U.S. Patent No. 9,266,951. United States Patent and Trademark Office.
-
U.S. Patent No. 9,556,153. United States Patent and Trademark Office.
-
U.S. Patent No. 10,183,020. United States Patent and Trademark Office.
-
Wunderink, R. G., et al. (2018). Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections. Clinical Infectious Diseases, 68(11), 1931-1939.